Published in final edited form as:

Mol Cancer Ther. 2015 June ; 14(6): 1273–1275. doi:10.1158/1535-7163.MCT-15-0271.

The Myb-p300 Interaction is a Novel Molecular Pharmacologic Target

Xi Liu¹, Kathryn A. Gold¹, and Ethan Dmitrovsky^{1,2}

¹Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030

²Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030

There are large and growing numbers of molecularly targeted agents under study in oncology. Yet, the nature of the pathways targeted in the cancer clinic should be broadened (1). Success stories include the discoveries of antagonists that affect growth factor receptors and enzymes that are either overexpressed or mutated relative to their normal counterparts. These proteins function as oncogenic changes that drive the growth, survival or abnormal differentiation state of a specific cancer. Clinical examples of this include HER2-targeted treatments of breast cancer (2), inhibitors of BRAF in melanoma (3), or antagonists of the epidermal growth factor receptor (EGFR) and its tyrosine kinase in lung cancer (4), to cite a few of many possible ones. However, most cancers diagnosed in patients do not harbor such alterations. Hence, other biochemical pathways that interfere with aberrant growth of cancers must be found.

One way to expand the spectrum of such targets is to disrupt protein-protein interactions. This is the case when cancers depend on them for their growth, maturation or survival. Promising antineoplastic strategies would then be uncovered. Indeed, targets once considered intractable would become exposed. This is why the study of Uttarkar and colleagues (5) is noteworthy. They revealed a way to interfere with the oncogenic effects of one of the earliest known oncogenes, *Myb* (6). This oncogene was previously considered an unattractive pharmacologic target. They accomplished the feat of showing that Myb is amenable to interference by exploiting a critical c-Myb protein-protein interaction. This builds on prior work that showed Myb-dependent gene expression was inhibited by the sesquiterpene lactone mexicanin-1 (7).

Myb functions as a transcription factor via binding to its genomic binding site t/cAACT/gG (8). Myb also interacts with the coactivators CBP or p300 to regulate gene expression (9,10). The KIX domain of p300 interacts with a LXXLL motif in the transactivation domain of c-Myb (11). More than 80 Myb target genes exist and are placed into three functional groups.

Corresponding Author: Ethan Dmitrovsky, MD, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street. Unit 1492, Houston, TX, 77030. Phone: 713-745-4495
edmitrovsky@mdanderson.org.

Disclosure of Potential Conflict of Interest

The authors have no potential conflicts of interest to disclose.

These include housekeeping genes such as MAT2A and GSTM1, cell lineage and differentiation gene products as for instance ELA2, MIM1, CD4 and PTCRA as well as species involved in the carcinogenesis process like MYC, Cyclin A1, Cyclin E, KIT, BCL2, HSPA5 and GATA3 (12,13).

Myb was initially identified as a retroviral oncogene (v-Myb) of avian myeloblastosis virus (17). It has vital functional roles in diverse malignancies. For example, Myb is highly expressed in hematopoietic progenitor cells, and its forced overexpression blocks differentiation and promotes leukemic cell transformation (15). Leukemic cells often depend on high basal c-Myb protein expression for their survival (18). Myb also has a major role in the development of several solid tumors. It is overexpressed in more than 80% of colorectal cancers (19). This expression profile predicts an unfavorable clinical outcome (20). Myb is detected in subsets of breast cancers and is associated with expression of the estrogen receptor- α (ER α) (21) in part because Myb is a direct ER α target (22). Myb oncogene addiction in leukemia and its expression in other cancers provided a rational basis for targeting Myb in cancer therapeutics.

Naphthol AS-E phosphate is an organophosphate. It was first used in histochemical experiments to quantify alkaline and acid phosphatase activities in polyacrylamide membrane model systems (23). Its biological activity was found when Naphthol AS-E phosphate was determined to disrupt the interaction between the CREB and CBP complex and attenuate target gene expression in response to exposure to a cAMP agonist (24). Naphthol AS-E phosphate is now shown to interfere with binding between the KID domain of CREB and the KIX domain of CBP (5). This intriguing work established that a small molecule is able to disrupt this protein–protein interaction in the nucleus. This interferes with subsequent signaling cascades. In turn this establishes a biochemical basis for targeting interactions between Myb and p300 because the KIX domain of p300 complexes with Myb in hematopoietic cells (25).

Uttarkar and coworkers (5) used the bacterial autodisplay assay to discern an interaction between Myb and the KIX domain of p300. They built on this experimental approach by showing Naphthol AS-E phosphate antagonizes this association and by this represses Myb transcriptional activity. Using microscale thermophoresis, these investigators determined the dissociation constant for the Myb-KIX association ($\sim 2.5 \mu\text{M}$) and IC₅₀ for inhibition of the Myb-KIX interaction by Naphthol AS-E phosphate ($\sim 30 \mu\text{M}$). These findings were extended by studying the human myeloid leukemia cell lines HL60, U937 and NB4. These studies determined that treatment with Naphthol AS-E phosphate is able to trigger differentiation and to reduce expression of c-Myc and Ada, which are Myb target genes. Apoptosis was also conferred by treatments of these leukemic cell lines. However, this was observed at a relatively high Naphthol AS-E phosphate concentration ($\sim 25 \mu\text{M}$).

There are several notable aspects of this study. One is that the autodisplay assay is a powerful way to identify specific protein interactions. This technology takes advantage of E.coli bacteria to express recombinant proteins at high levels on the cell surface, which allows for functional readout of a desired protein interaction (26). This team used this assay

to identify the Myb-KIX association and to measure the dissociation constant and IC₅₀ of Naphthol AS-E phosphate. A key aspect of this work was to confirm it is possible to antagonize the Myb oncoprotein with a small molecule inhibitor (5). While their study employed the tool compound (Naphthol AS-E phosphate) further work is needed to develop a clinical lead compound that would selectively inhibit Myb in the cancer clinic.

Some limitations in the current work could be addressed in future studies. For instance, selectivity and specificity of Naphthol AS-E phosphate for the Myb-KIX interaction needs to be determined. Naphthol AS-E phosphate does disrupt interactions between this transcription factor and the KIX domain of CBP/p300. However, the current study does not exclude the possibility that Naphthol AS-E phosphate effects on Myb target gene expression, differentiation and apoptosis are conferred by mechanisms other than those affecting Myb-CRB or another transcript factor (CREB and c-Jun) interaction with the KIX domain of p300/CBP (27). In this regard, it is relevant that the Myb-CBP binding K_d is 0.65 μ M, but the Myb-p300 binding is higher (K_d = 2.5 μ M). Some antineoplastic activities of Naphthol AS-E phosphate occur at high dosages, indicating that Myb-p300 off-target effects are potentially engaged.

Whether other KIX domain interactions are involved needs to be learned. Naphthol AS-E phosphate was shown to suppress Myb target genes expression and induce differentiation at concentrations as low as 5 μ M, but apoptosis was not prominently detected until higher dosages were used (5). This underscores the possible off-target actions of this agent. Additional mechanistic studies would establish whether Naphthol AS-E phosphate pharmacodynamic activities in myeloid leukemic cells depend on disrupting the Myb-p300 association. This can be accomplished by performing gain versus loss of Myb and/or p300 functional studies as a way to discern consequences on leukemic cell proliferation, apoptosis and differentiation. The knowledge obtained from these analyses would help guide development of agents with even greater ability than Naphthol AS-E phosphate to antagonize Myb-p300 protein interactions.

In summary, Naphthol AS-E phosphate disrupts interactions between Myb and the KIX domain of p300. The result of this includes induced myeloid leukemia cell differentiation and apoptosis. Taken together, the current work (5) underscores the value of identifying innovative molecular pharmacologic targets like Myb. It is notable that Myb is a candidate therapeutic target in malignancies beyond leukemia. Future work should identify agents with more favorable properties than Naphthol AS-E phosphate in antagonizing Myb activity. This would certainly broaden the scope of pharmacologic tools available to combat cancer.

References

1. Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. *Nature Reviews Cancer*. 2012; 12:237–51. [PubMed: 22437869]
2. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. *New Engl J Med*. 2001; 344:783–92. [PubMed: 11248153]
3. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. *New Engl J Med*. 2011; 364:2507–16. [PubMed: 21639808]

4. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. *New Engl J Med*. 2004; 350:2129–39. [PubMed: 15118073]
5. Uttarkar S, Dukare S, Bopp B, Goblirsch M, Jose J, Klempnauer K-H. Naphthol AS-E phosphate inhibits the activity of the transcription factor Myb by blocking the interaction with the KIX domain of the coactivator p300. *Molecular Cancer Therapeutics*. in press.
6. Ramsay RG, Gonda TJ. MYB function in normal and cancer cells. *Nature Reviews Cancer*. 2008; 8:523–34. [PubMed: 18574464]
7. Bujnicki T, Wilczek C, Schomburg C, Feldmann F, Schlenke P, Müller-Tidow C, et al. Inhibition of Myb-dependent gene expression by the sesquiterpene lactone mexicanin-1. *Leukemia*. 2012; 26:615–22. [PubMed: 21986841]
8. Biedenkapp H, Borgmeyer U, Sippel AE, Klempnauer KH. Viral myb oncogene encodes a sequence-specific DNA-binding activity. *Nature*. 1988; 335:835–7. [PubMed: 3185713]
9. Oelgeschläger M, Janknecht R, Krieg J, Schreek S, Luscher B. Interaction of the co-activator CBP with Myb proteins: effects on Myb-specific transactivation and on the cooperativity with NF-M. *The EMBO journal*. 1996; 15:2771–80. [PubMed: 8654374]
10. Dai P, Akimaru H, Tanaka Y, Hou DX, Yasukawa T, KaneiIshii C, et al. CBP as a transcriptional coactivator of c-Myb. *Gene Dev*. 1996; 10:528–40. [PubMed: 8598284]
11. Zor T, De Guzman RN, Dyson HJ, Wright PE. Solution structure of the KIX domain of CBP bound to the transactivation domain of c-Myb. *J Mol Biol*. 2004; 337:521–34. [PubMed: 15019774]
12. Lei W, Rushton JJ, Davis LM, Liu F, Ness SA. Positive and negative determinants of target gene specificity in myb transcription factors. *Journal of Biological Chemistry*. 2004; 279:29519–27. [PubMed: 15105423]
13. Liu F, Lei W, O'Rourke JP, Ness SA. Oncogenic mutations cause dramatic, qualitative changes in the transcriptional activity of c-Myb. *Oncogene*. 2006; 25:795–805. [PubMed: 16205643]
14. Westin EH, Gallo RC, Arya SK, Eva A, Souza LM, Baluda MA, et al. Differential expression of the amv gene in human hematopoietic cells. *Proceedings of the National Academy of Sciences (USA)*. 1982; 79:2194–8.
15. Introna M, Golay J. How can oncogenic transcription factors cause cancer: a critical review of the myb story. *Leukemia*. 1999; 13:1301–6. [PubMed: 10482978]
16. Malaterre J, Carpinelli M, Ernst M, Alexander W, Cooke M, Sutton S, et al. c-Myb is required for progenitor cell homeostasis in colonic crypts. *Proceedings of the National Academy of Sciences (USA)*. 2007; 104:3829–34.
17. Weinstein Y, Ihle JN, Lavu S, Reddy EP. Truncation of the c-Myb gene by a retroviral integration in an interleukin 3-dependent myeloid-leukemia cell line. *Proceedings of the National Academy of Sciences (USA)*. 1986; 83:5010–4.
18. Leprince D, Gégonne A, Coll J, de Taisne C, Schneeberger A, Lagrou C, et al. A putative second cell-derived oncogene of the avian leukaemia retrovirus E26. *Nature*. 1983; 306:395–7. [PubMed: 6316156]
19. Ramsay RG, Barton AL, Gonda TJ. Targeting c-Myb expression in human disease. *Expert Opinion on Therapeutic Targets*. 2003; 7:235–48. [PubMed: 12667100]
20. Biroccio A, Benassi B, D'Agnano I, D'Angelo C, Buglioni S, Mottolese M, et al. c-Myb and Bcl-x overexpression predicts poor prognosis in colorectal cancer: clinical and experimental findings. *American Journal of Pathology*. 2001; 158:1289–99. [PubMed: 11290547]
21. Guerin M, Sheng ZM, Andrieu N, Riou G. Strong association between c-myb and oestrogen-receptor expression in human breast cancer. *Oncogene*. 1990; 5:131–5. [PubMed: 2181374]
22. Frasar J, Danes JM, Komm B, Chang KCN, Lyttle CR, Katzenellenbogen BS. Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: Insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. *Endocrinology*. 2003; 144:4562–74. [PubMed: 12959972]
23. Lojda Z, Van der Ploeg M, Van Duijn P. Phosphates of the naphthol AS series in the quantitative determination of alkaline and acid phosphatase activities “in situ” studied in polyacrylamide

membrane model systems and by cytospectrophotometry. *Histochemie Histochemistry Histochemie*. 1967; 11:13–32. [PubMed: 5589640]

24. Best JL, Amezcua CA, Mayr B, Flechner L, Murawsky CM, Emerson B, et al. Identification of small-molecule antagonists that inhibit an activator: coactivator interaction. *Proceedings of the National Academy of Sciences (USA)*. 2004; 101:17622–7.
25. Kasper LH, Fukuyama T, Lerach S, Chang YC, Xu W, Wu S, et al. Genetic interaction between mutations in c-Myb and the KIX domains of CBP and p300 affects multiple blood cell lineages and influences both gene activation and repression. *Plos One*. 2013; 8
26. Jose J. Autodisplay: efficient bacterial surface display of recombinant proteins. *Appl Microbiol Biot*. 2006; 69:607–14.
27. Thakur JK, Yadav A, Yadav G. Molecular recognition by the KIX domain and its role in gene regulation. *Nucleic Acids Res*. 2014; 42:2112–25. [PubMed: 24253305]